Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
|Videos|August 16, 2022
Early Intervention Strategies for Bipolar Disorder: Identifying Warning Signs
Author(s)Christopher Schneck, MD
What is a mood disorder and what are the early warning signs? What treatments are available?
Advertisement
Christopher Schneck, MD, gives a summary on his talk on bipolar disorder from the
Dr Schneck is the Division Head of Adult Psychiatry, the Chief of Service at CU Medicine Adult Outpatient Psychiatry, and Medical Director at the Helen and Arthur E. Johnson Depression Center Behavioral Health Director.
Advertisement
Related to this article
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement